Malarone

Atovaquone/proguanil, the active ingredient in Malarone, is an antimalarial presented as an oral tablet for oral use. It is indicated for the prevention of malaria infection and for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum in travelers and residents of endemic regions.

GNH USA supplies Malarone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Malarone is an antimalarial drug used in both prophylaxis and treatment of malaria infections.

- Prevention of malaria infection: provides prophylactic protection for travelers to endemic regions. - Treatment of acute uncomplicated malaria caused by Plasmodium falciparum: clears infection after confirmed diagnosis. - Chemoprophylaxis for travelers to endemic areas: maintains therapeutic drug levels during exposure to malaria‑risk zones.

Malarone may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Abdominal pain: cramping or discomfort in the abdomen. - Vomiting: occasional expulsion of stomach contents. - Loss of appetite: reduced desire to eat. - Metallic taste: altered taste sensation.

Serious or Rare Side Effects: - Severe skin reactions (e.g., Stevens‑Johnson syndrome): requires immediate medical attention. - Hepatic enzyme elevation: may indicate liver stress. - Hemolytic anemia: especially in patients with G6PD deficiency. - Neutropenia: reduced white blood cell count. - Hypersensitivity reactions: including rash, fever, or anaphylaxis. - Renal impairment: worsening kidney function in susceptible individuals.

Before using Malarone, consider the following safety measures.

- Pregnancy: consult a healthcare provider; safety data are limited. - Renal impairment: dose adjustment may be required in patients with reduced kidney function. - Hepatic impairment: use with caution in patients with liver disease. - Age restrictions: not recommended for children weighing less than 5 kg. - Drug resistance: avoid using Malarone as monotherapy for malaria prophylaxis. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Malarone can interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Rifampin: significantly reduces atovaquone plasma concentrations, compromising efficacy. - Cimetidine: may increase atovaquone levels, raising risk of toxicity. - Protease inhibitors (e.g., ritonavir): can lower drug exposure, reducing therapeutic effect.

Moderate Interactions (Monitor Closely): - Warfarin: may potentiate anticoagulant effect, requiring INR monitoring. - Phenytoin: may decrease atovaquone concentrations, necessitating efficacy assessment. - Macrolide antibiotics (e.g., erythromycin): may affect metabolism and require clinical observation.